Search Results - "лекарственная гепатотоксичность"

Source: Rational Pharmacotherapy in Cardiology; Vol 15, No 5 (2019); 675-680 ; Рациональная Фармакотерапия в Кардиологии; Vol 15, No 5 (2019); 675-680 ; 2225-3653 ; 1819-6446

Subject Terms: drug hepatotoxicity, rivaroxaban, dabigatran, apixaban, atrial fibrillation, randomized trials, лекарственная гепатотоксичность, ривароксабан, дабигатран, апиксабан, фибрилляция предсердий, рандомизированные исследования

File Description: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2038/1868; Harder S., Graff J. Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol. 2013;69:1617-33. DOI:10.1007/s00228-013-1510-z.; Tajiri K., Shimizu Y. Practical guidelines for diagnosis and early management of druginduced liver injury. World J Gastroenterol. 2008;14(44):6774-85. DOI:10.3748/wjg.14.6774.; Navarro V.J., Senior J.R. Drug-related hepatotoxicity. N Engl J Med. 2006;354(7):731-9. DOI:10.1056/NEJMra052270.; Lauschke V., Ingelman-Sundberg M. The importance of patient-specific factors for hepatic drug response and toxicity. Int J Mol Sci. 2016;17:1714. DOI:10.3390/ijms17101714.; Goldberg D.S., Forde K.A., Carbonari D.M., et al. Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system. Gastroenterology. 2015;148:1353-61. DOI:10.1053/j.gastro.2015.02.050.; Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990;11(2):272-6. DOI:10.1016/0168-8278(90)90124-A.; Aithal G.P., Watkins P.B., Andrade R.J., et al. Case definition and phenotype standardization in druginduced liver injury. Clin Pharmacol Ther. 2011;89(6):806-15. DOI:10.1038/clpt.2011.; Liakoni E., Ratz Bravo A.E., Krahenbuhl S. Hepatotoxicity of new oral anticoagulants (NOACs). Drug Saf. 2015;38:711-20. DOI:10.1007/s40264-015-0317-5.; Agnelli G., Eriksson B.I., Cohen A.T., et al. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb Res. 2009;123:488-97. DOI:10.1016/j.thromres.2008.02.017.; Turpie A.G., Lassen M.R., Davidson B.L., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373:1673-80. DOI:10.1016/S0140-6736(09)60734-0.; Watkins P.B., Desai M., Berkowitz S.D., et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf. 2011;34:243-52. DOI:10.2165/11586600-000000000-00000.; Caldeira D., Barra M., Santos A.T., et al. Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. Heart. 2014;100:550-6. DOI:10.1136/heartjnl-2013-305288.; Alonso A., MacLehose R.F., Chen L.Y., et al. Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation. Heart. 2017;103:834-9. DOI:10.1136/heartjnl-2016-310586.; Raschi E., Poluzzi E., Koci A., et al. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. Br J Clin Pharmacol. 2015;80:285-93. DOI:10.1111/bcp.12611.; Licata A., Puccia F., Lombardo V., et al. Rivaroxaban-induced hepatotoxicity: review of the literature and report of new cases. Eur J Gastroenterol Hepatol. 2018;30(2):226-32. DOI:10.1097/MEG.0000000000001030.; Cordeanu M., Gaertner S., Bensalah N., et al. Rivaroxaban induced liver injury: a cholestatic pattern. Int J Cardiol. 2016;216:97-8. DOI:10.1016/j.ijcard.2016.04.063.; Lambert A., Cordeanu M., Gaertner S., et al. Rivaroxaban-induced liver injury: results from a venous thromboembolism registry. Int J Cardiol. 2015;191:265-6. DOI:10.1016/j.ijcard.2015.04.248.; Glenn K., Chen P., Musleh M., et al. A rare case of rivaroxaban causing delayed symptomatic hepatocellular injury and hyperbilirubinemia. Case Rep Gastrointest Med 2017; 2017: 5678187. DOI:10.1155/2017/5678187.; Baig M., Wool K.J., Halanych J.H., et al. Acute liver failure after initiation of rivaroxaban: a case report and review of the literature. N Am J Med Sci. 2015;7:407-10. DOI:10.4103/1947-2714.166221.; Tujios S., Fontana R.J. Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol. 2011;8:202-11. DOI:10.1038/nrgastro.2011.22.; Leise M.D., Poterucha J.J., Talwalkar J.A. Drug-induced liver injury. Mayo Clin Proc. 2014;89:95- 106. DOI:10.1016/j.mayocp.2013.09.016.; Godoy P., Hewitt N.J., Albrecht U., et al. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol. 2013;87:1315-530. DOI:10.1007/s00204-013-1078-5.; Gong I.Y., Kim R.B. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol. 2013;29:S24-33. DOI:10.1016/j.cjca.2013.04.002.; https://www.rpcardio.com/jour/article/view/2038

Availability: https://www.rpcardio.com/jour/article/view/2038

View record from BASE

5

Academic Journal